Phase I Safety Study of Anti-HIV Immune Serum Globulin (Human)

Completed · Phase 1

Conditions studied: HIV Infections

In brief

To investigate the potential benefit of providing passive immunity with hyperimmune anti-HIV human serum.

Key facts

Study ID

NCT00002036

Run by

Abbott

People needed

12

Last updated by the study team

2009-02-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients must have:
• Proof of HIV infection.
• Diagnosis of asymptomatic HIV infection or early AIDS related complex (ARC) with no zidovudine (AZT) or other anti-HIV therapy. OR a diagnosis of AIDS and = or > 3 months of AZT therapy.

You may not qualify if…

• Co-existing Condition:
• Patients with the following conditions or symptoms are excluded:
• HIV-induced neurological disease.
• IgA negative.
• Concurrent Medication:
• Excluded:
• Immunomodulating agents.
• Steroids.
• Interferons.
• Patients with the following are excluded:
• Active substance abuse.
• Use of immunomodulating drugs such as steroids or interferons.
• HIV-induced neurological disease.
• IgA negative.
• Required with a diagnosis of AIDS:
• = or > 3 months of zidovudine (AZT) therapy.
• Active substance abuse.

Where it is running

• Univ of Minnesota — Minneapolis, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.